We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Philips Sells MR-HIFU Business to Profound Medical

By HospiMedica International staff writers
Posted on 15 Aug 2017
Royal Philips (Amsterdam, the Netherlands) has completed the sale of its Sonalleve MR-HIFU business to Profound Medical Inc. (Ontario, Canada).

Sonalleve MR-HIFU is an innovative therapeutic platform that combines real-time Magnetic Resonance Imaging (MRI) and thermometry with high intensity focused ultrasound to enable precise and incision-free ablation of diseased tissue. With the completion of this acquisition, Profound has become the only company to provide a therapeutics platform that provides the precision of real-time MRI combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue.

Image: The Sonalleve MR-HIFU system (Photo courtesy of Philips Healthcare).
Image: The Sonalleve MR-HIFU system (Photo courtesy of Philips Healthcare).

Philips will continue to distribute Profound’s TULSA-PRO system, which combines real-time MRI with transurethral, robotically driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects.

“We are excited about our enhanced close collaboration with Profound, as we aim to accelerate the development of new clinical applications and address the evolving needs of our current and future customers,” said Rob Cascella, Chief Business Leader Diagnosis and Treatment at Philips.

“This transaction with Philips is truly transformative for Profound, and represents an opportunity for us to immediately transition from a development-stage to a growth-stage company,” said Dr. Arun Menawat, Profound’s CEO. “From a commercial perspective, our strengthened MR-Ultrasound ablation technology platform not only benefits Profound by significantly increasing the total opportunity size and creating synergies, but also benefits hospital customers by providing them with the ability to better utilize their MR system assets. In addition to the contribution the acquisition of the Sonalleve MR-HIFU business will make to our revenue base, we believe that it will also help accelerate our growth going forward.”


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Mini C-arm Imaging System
Fluoroscan InSight FD
New
LED Surgical Light
Convelar 1670 LED+/1675 LED+/1677 LED+

Latest Business News

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024

Boston Scientific to Acquire AFib Ablation Company Cortex